Barchart.com
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
18.56 x 10 21.21 x 1
Post-market by (Cboe BZX)
19.93 -0.05 (-0.25%) 03/28/25 [NASDAQ]
18.56 x 10 21.21 x 1
Post-market 19.93 unch (unch) 16:03 ET
News & Headlines for Fri, Mar 28th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences Yolowire - Wed Mar 5, 2:13PM CST

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 30.28 (-1.82%)
CLDX : 19.93 (-0.25%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences Yolowire - Wed Mar 5, 2:13PM CST

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 30.28 (-1.82%)
CLDX : 19.93 (-0.25%)
Celldex Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire - Tue Mar 4, 7:01AM CST

CLDX : 19.93 (-0.25%)
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 GlobeNewswire - Mon Mar 3, 7:01AM CST

CLDX : 19.93 (-0.25%)
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 GlobeNewswire - Sat Mar 1, 11:45AM CST

CLDX : 19.93 (-0.25%)
Celldex: Q4 Earnings Snapshot AP - Thu Feb 27, 3:32PM CST

Celldex: Q4 Earnings Snapshot

CLDX : 19.93 (-0.25%)
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update GlobeNewswire - Thu Feb 27, 3:01PM CST

CLDX : 19.93 (-0.25%)
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment Quiver Quantitative, Inc. - Thu Dec 19, 2024

Celldex Therapeutics initiates Phase 2 study of barzolvolimab for treating atopic dermatitis, currently enrolling patients.Quiver AI SummaryCelldex Therapeutics has launched a Phase 2 study of its monoclonal...

CLDX : 19.93 (-0.25%)
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis GlobeNewswire - Thu Dec 19, 2024

CLDX : 19.93 (-0.25%)
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation Quiver Quantitative, Inc. - Wed Nov 20, 2024

Celldex Therapeutics began Phase 1a study of CDX-622, targeting chronic inflammation through a bispecific antibody approach.Quiver AI SummaryCelldex Therapeutics, Inc. has announced the commencement of...

CLDX : 19.93 (-0.25%)

Barchart Exclusives

Trump Tariffs, Tesla Deliveries and Other Key Things to Watch this Week Barchart - Sun Mar 30, 6:38PM CDT
The S&P 500 suffered more selling on Friday after a hot inflation report and weak consumer sentiment spooked investors. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies
Wed, Apr 02, 2025 5:00 PM UTC
Reserve Your Spot